The University of Texas at Arlington (UTA) received a $451,996 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to develop an integrated high-throughput platform for quantitative cellular and molecular analysis of treatment-resistant glioblastoma (brain cancer) cells. The goals of this 3-year project, starting on February 1, 2025, are to (1) employ an ex vivo platform to analyze biophysical properties and screen for novel therapies targeting migrating and treatment-resistant glioblastoma cells, and (2) establish a pipeline for target identification and drug discovery using this system. The project aims to revolutionize drug discovery for resistant brain cancer by reliably inducing and enriching treatment-resistant cancer cells, and enabling high-throughput screening of potential drug candidates. Additionally, the project will provide research opportunities for undergraduate students, contributing to the development of a diverse biomedical research workforce.
Generated 3/4/25, 6:29 AM